ImmunityBio Navigates Clinical Progress Amid Regulatory Scrutiny

ImmunityBio faces FDA warning and investor lawsuits over Anktiva claims, while an independent review confirms its key bladder cancer trial remains on track for a 2026 regulatory filing.

ImmunityBio finds itself at a critical juncture, balancing a significant clinical milestone against mounting legal and regulatory challenges. The biopharmaceutical company's stock, while demonstrating remarkable year-to-date performance, faces volatility as it addresses a formal FDA warning and a series of investor lawsuits.

Legal Challenges Emerge Following FDA Action

The company's recent regulatory troubles began on March 24, 2024, when the U.S. Food and Drug Administration issued a formal warning letter to ImmunityBio. The agency cited promotional claims that allegedly attributed capabilities to its drug Anktiva beyond its approved uses. This development triggered a sharp sell-off, with the equity losing over 21% of its value. In recent trading, shares settled at $7.38, marking a decline of approximately 13% across a five-session period.

In the wake of this action, several law firms have filed class-action suits on behalf of investors. The litigation pertains to shareholders who purchased securities between January 19 and March 25, 2026. The core allegation is that the company made misleading statements concerning the preventative and curative properties of Anktiva outside its authorized indications. Investors have until May 26, 2026, to petition for lead plaintiff status in these proceedings.

Independent Review Confirms Trial Strength

Amid this backdrop, ImmunityBio received validating news from its clinical program. An independent data monitoring committee (IDMC) conducted a scheduled review of the Phase 2b trial known as QUILT-2.005. The committee examined data from 183 of the total 366 participants. It concluded that the study possesses sufficient statistical power to meet its primary endpoints without needing to enroll additional patients. The trial is evaluating the efficacy of Anktiva in combination with BCG for the treatment of bladder cancer.

This outcome provides a solid foundation for the company's regulatory strategy. ImmunityBio plans to utilize these study results to support a supplemental Biologics License Application (sBLA) with the FDA, which is targeted for submission in 2026. Anktiva previously secured its initial FDA approval for certain bladder cancer indications in 2024.

Conflicting Signals Shape Investment Outlook

The company now operates under a tight timeline, with roughly 15 days to formally respond to the FDA's warning letter. How management navigates these concurrent regulatory and legal hurdles will be pivotal in determining whether the planned sBLA can be filed as scheduled this year.

Despite recent pressure, the stock's performance in 2024 has been notably strong, boasting a gain of about 273% since the start of the year. This volatility has not deterred some analysts from maintaining a positive view. Research firms BTIG and Piper Sandler have issued price targets of $13 and $12 per share, respectively, indicating their belief in the company's underlying value and clinical prospects.